Fig. 6From: Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia modelsWestern blot analysis of a p53, cleaved caspase-3, and Mcl-1 protein expression in MOLM-13 cells and b Mcl-1 protein expression in MV4-11 cells exposed to venetoclax (100Â nM) and idasanutlin (100Â nM) alone or in combination for time periods indicated. Actin was used as a loading control for both cell linesBack to article page